https://orcid.org/0000-0002-3034-3042Dr. Spreafico is Associate Professor at the University of Toronto and Staff Medical Oncologist and Clinician-Investigator in the Department of Medical Oncology and Hematology at the Princess Margaret Cancer Centre University Health Network in Toronto, Canada. Dr. Spreafico previous trainings include: a PhD in translational research in the Program for Evaluation of Targeted Therapies at the University of Colorado, and a subspecialty fellowship in experimental therapeutics, head and neck (HN) cancer, skin/melanoma at the Princess Margaret Cancer Centre, Toronto. Dr. Spreafico is the HN medical oncology disease site lead and Director of the Phase I Drug Development Fellowship at the Princess Margaret Cancer Centre. Dr. Spreafico is a member of the Canadian Cancer Trial Group (CCTG) Head and Neck Disease site Executive Committee. She serves on the US NCI Head and Neck Cancer Steering Committee rare tumor task force, and she is the Co-Chair of the NRG Oncology Recurrent/Metastatic HN Cancer Working Group.
Dr. Spreafico's full-time academic practice and research include early phase clinical trials, with disease-specific interests in skin/melanoma, and head and neck cancers. Her translational research focuses on immuno-oncology-based, microbiome and cancer interception-driven studies. Dr. Spreafico leads as PI Canadian Cancer Trial Group, NRG and NCI CTEP early phase investigator-initiated clinical trials. She is the recipient of several national and international awards and has published multiple peer-reviewed publications in widely cited journals. Dr. Spreafico developed, launched and continues to direct ARTES, a leadership course to provide education and coaching of soft skills to early career investigators across North America Institutions within multiple US NCI UM1 Consortia sites. Annually, the ARTES course continues to successfully graduate 16-18 international early career investigators within medical, radiation and surgical oncology disciplines.